Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase. The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory. Reduction of the 16,17-double bond to give 17 beta-pyridyl derivatives diminished potency with 3-pyridyl substitution (3-->27; IC50 for lyase, 2.9-->23 nM) but increased it with a 4-pyridyl substituent present (10-->28; IC50 1 microM-->53 nM). In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3 beta-ol (3, Kiapp < 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM). Thus compounds having variously aromatic ring A (18), saturated rings A/B (21, 22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range. The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [11]
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Palladium-catalyzed cross-coupling reaction of organoboron compounds with organic triflates
Ohe, T., Miyaura, N., & Suzuki, A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00060a041 · Cited by 321
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS
Goldstein, A. (1944) · Journal of General Physiology · doi:10.1085/jgp.27.6.529 · Cited by 181
KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER
Trachtenberg, J., & Pont, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92909-x · Cited by 162
Steroid Hormones: A Practical Approach
(1989) · Tumori Journal · doi:10.1177/030089168907500230 · Cited by 100
Labrie, F., Belanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Is there a case for P-450 inhibitors in cancer treatment?
Wauwe, J. P. V., & Janssen, P. A. J. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a001 · Cited by 88
FORTI, G., SALERNO, R., MONETI, G., ZOPPI, S., FIORELLI, G., MARINONI, T., NATALI, A., COSTANTINI, A., SERIO, M., MARTINI, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Cited by
Items 201–300 of 403
Frank, É., Schneider, G., Kádár, Z., & Woelfling, J. (2009) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200900301 · Cited by 18
Agents That Target Androgen Synthesis in Castration-Resistant Prostate Cancer
Ferraldeschi, R., & Bono, J. S. D. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31827e0b6f · Cited by 18
Kotovshchikov, Y. N., Latyshev, G. V., Lukashev, N. V., & Beletskaya, I. P. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00404c · Cited by 18
Matsubara, N., Uemura, H., Fukui, I., Niwakawa, M., Yamaguchi, A., Iizuka, K., & Akaza, H. (2014) · Cancer Science · doi:10.1111/cas.12496 · Cited by 18
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Capper, C. P., Larios, J. M., Sikora, M. J., Johnson, M. D., & Rae, J. M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3774-3 · Cited by 22
Nnane, I. P., Kato, K., Liu, Y., Long, B. J., Lü, Q., Wang, X., Ling, Y., & Brodie, A. (1999) · Endocrinology · doi:10.1210/en.140.6.2891 · Cited by 18
Chen, F., Li, H., Wang, Y., Tang, X., Lin, K., Li, Q., Meng, C., Shi, W., Leo, J., Liang, X., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00952-z · Cited by 22
Ajduković, J. J., Jakimov, D., Rárová, L., Strnad, M., Dzichenka, Y. U., Usanov, S. A., Škorić, D., Jovanović-Šanta, S., & Sakač, M. N. (2021) · RSC Advances · doi:10.1039/d1ra07613b · Cited by 17
Ouzaïd, I., Ravery, V. V., Pouessel, D., & Culine, S. (2012) · The French Journal of Urology · doi:10.1016/j.purol.2012.07.007 · Cited by 18
New oxygen-containing androstane derivatives: Synthesis and biological potential
Savić, M. P., Kuzminac, I. Z., Škorić, D., Jakimov, D., Rárová, L., Sakač, M. N., & Djurendić, E. A. (2020) · Journal of Chemical Sciences · doi:10.1007/s12039-020-01803-3 · Cited by 18
Castrate-resistant prostate cancer: postdocetaxel management
Zhao, S. Q., & Yu, E. Y. (2013) · Current Opinion in Urology · doi:10.1097/mou.0b013e32835e2253 · Cited by 18
Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
Chen, M., Liang, Z.-J., Luo, D., Xue, K., Liao, D.-Y., Li, Z., Yu, Y., Chen, Z., & Zhao, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.843110 · Cited by 16
Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition
Krug, S. J., Hu, Q., & Hartmann, R. W. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.10.019 · Cited by 16
Nortcliffe, A., Fleming, I. N., Botting, N. P., & O’Hagan, D. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.09.004 · Cited by 16
Chao, J., Ling, Y., Liu, X., Luo, X., & Brodie, A. M. (2006) · Steroids · doi:10.1016/j.steroids.2006.02.004 · Cited by 16
Haidar, S., & Hartmann, R. W. (2002) · Archiv der Pharmazie · doi:10.1002/ardp.200290006 · Cited by 16
Ideyama, Y., Masafumi, K., Kyoko, T., Susaki, Y., Nanya, T., Takahito, N., Hiroko, I., Takashi, F., Akaza, H., & Shikama, H. (1999) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.79.213 · Cited by 18
Chung, E., Offei, S. D., Jia, U.-T. A., Estevez, J. C., Perez, Y., Arman, H. D., & Yoshimoto, F. K. (2021) · Steroids · doi:10.1016/j.steroids.2021.108952 · Cited by 16
Al-Masoudi, N. A., Ali, D. S., Saeed, B. A., Hartmann, R. W., Engel, M., Rashid, S., & Saeed, A. (2014) · Archiv der Pharmazie · doi:10.1002/ardp.201400255 · Cited by 15
Abiraterone acetate for castration resistant prostate cancer
Shah, S., & Ryan, C. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003639427 · Cited by 16
Koch, V., Nieger, M., & Bräse, S. (2017) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201601289 · Cited by 15
Fishman, M., Gupta, & Carballido (2011) · OncoTargets and Therapy · doi:10.2147/ott.s14107 · Cited by 21
Przezdziecka, A., Kurek‐Tyrlik, A., & Wicha, J. (2002) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc20021658 · Cited by 15
Pyridine indole hybrids as novel potent CYP17A1 inhibitors
Wróbel, T. M., Grudzińska, A., Yakubu, J., du Toit, T., Sharma, K., Harrington, J. C., Björkling, F., Jørgensen, F. S., & Pandey, A. V. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2463014 · Cited by 17
Iványi, Z., Szabó, N., Woelfling, J., Szécsi, M., Julesz, J., & Schneider, G. (2012) · Steroids · doi:10.1016/j.steroids.2012.07.001 · Cited by 14
Synthesis of 21-nitrogen substituted pregna-5,17(20)-dienes from pregnenolone
Stulov, S. V., Tkachev, Y. V., Новиков, Р. А., Zavialova, M. G., Timofeev, V. P., & Misharin, A. Y. (2011) · Steroids · doi:10.1016/j.steroids.2011.10.007 · Cited by 14
Prostate cancer: Review in 2014
Delongchamps, N. B. (2014) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2014.06.005 · Cited by 14
Szánti‐Pintér, E., Maksó, L., Gömöry, Á., Wouters, J., Herman, B. E., Szécsi, M., Mikle, G., Kollár, L., & Skoda‐Földes, R. (2017) · Steroids · doi:10.1016/j.steroids.2017.05.006 · Cited by 14
Newell, D. R., Searle, K. M., Westwood, N., & Burtles, S. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601106 · Cited by 15
Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
Kuzminac, I. Z., Nikolić, A. R., Savić, M. P., & Ajduković, J. J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111401 · Cited by 19
Yi, Q., Han, X., Yu, H. G., Chen, H.-Y., Qiu, D., Su, J., Lin, R., Batist, G., & Wu, J. H. (2024) · Oncogene · doi:10.1038/s41388-024-02944-2 · Cited by 14
New treatment options for patients with metastatic castration-resistant prostate cancer
Higano, C. S. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.007 · Cited by 14
Improved Procedure for Preparation of Abiraterone Acetate
Madhra, M. K., Sriram, H. M., Inamdar, M., Sharma, M. K., Prasad, M., & Joseph, S. (2014) · Organic Process Research & Development · doi:10.1021/op500044p · Cited by 13
Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
Liu, J. J., & Zhang, J. (2013) · Cancer Control · doi:10.1177/107327481302000306 · Cited by 14
Kaku, T., Matsunaga, N., Ojida, A., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., & Tasaka, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.017 · Cited by 14
Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer
Zivi, A., Massard, C., & Bono, J. S. D. (2010) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2010.n.003 · Cited by 12
Björklund, E., Larsson, T. N. L., Jacobsson, S. O. P., & Fowler, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087542 · Cited by 13
Blass, B. E., Iyer, P. S., Abou-Gharbia, M. A., Childers, W. E., Gordon, J. C., Ramanjulu, M. M., Morton, G. C., Arumugam, P., Boruwa, J., Ellingboe, J. W., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.040 · Cited by 12
Pandey, M., Cuddihy, G., Gordon, J. A., Cox, M., & Wasan, K. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091509 · Cited by 14
New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer
Ezzell, E. E., Chang, K. S., & George, B. J. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0305-9 · Cited by 11
Pd-catalyzed alkylation of halogen-substituted steroids with organozinc compounds
Latyshev, G. V., Lukashev, N. V., & Beletskaya, I. P. (2008) · Russian Journal of Organic Chemistry · doi:10.1134/s107042800806002x · Cited by 11
Kim, W., Jones, J. O., Diamond, M., Haqq, C., Molina, A., Small, E. J., & Ryan, C. J. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.27 · Cited by 11
Chen, S., Wu, H., Li, A., Pei, J., & Zhao, L. (2018) · Research on Chemical Intermediates · doi:10.1007/s11164-018-3539-1 · Cited by 10
Palladium-Catalyzed Synthesis and Anticancer Activity of Paclitaxel–Dehydroepiandrosterone Hybrids
Lou, S.-J., Li, X., Zhou, X., Fang, D., & Gao, F. (2020) · ACS Omega · doi:10.1021/acsomega.0c00558 · Cited by 11
Kampschulte, N., Berking, T., Celik, I.-E., Kirsch, S. F., & Schebb, N. H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114332 · Cited by 10
Ahmed, S. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00077-2 · Cited by 10
Mahdi, K. M., Abdul‐Reda, N. A., & Al-Masoudi, N. A. (2015) · European Journal of Chemistry · doi:10.5155/eurjchem.6.1.1-7.1139 · Cited by 9
Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents
Wróbel, T. M., Rogova, O., Andersen, K. L., Yadav, R., Brixius‐Anderko, S., Scott, E. E., Olsen, L., Jørgensen, F. S., & Björkling, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144868 · Cited by 9
Stulov, S. V., Mankevich, O. V., Новиков, Р. А., Tkachev, Y. V., Timofeev, V. P., Dugin, N. O., Pozdnev, V. F., Fedyushkina, I. V., Scherbinin, D. S., Veselovsky, A. V., et al. (2013) · Steroids · doi:10.1016/j.steroids.2013.02.014 · Cited by 9
Structure activity relationship study of known inhibitors of the enzyme 5α-reductase (5AR)
Ahmed, S., & Denison, S. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00044-4 · Cited by 9
The Role of Natural Chalcones and Their Derivatives in Targeting Prostate Cancer: Recent Updates
Hussein, O., Elkhalifa, D. H., Hassan, A. F., Alali, F. Q., Moustafa, A. A., & Khalil, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412082 · Cited by 9
Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
Zhu, J., Luo, G., & Xiang, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03005 · Cited by 10
Zeng, C., Xu, S., Shen, J., Zhao, S., Xu, X., & Peng, L. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c03557 · Cited by 8
M0CRPC overview of management options
Heß-Busch, Y., Hadaschik, B. A., & Hess, J. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02997-z · Cited by 8
Pyridine ring as an important scaffold in anticancer drugs
Elagamy, A., Elghoneimy, L. K., & Arafa, R. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91221-1.00004-x · Cited by 10
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer
Hu, Q., & Hartmann, R. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00011-5 · Cited by 10
Clayton, R., Wu, J. S.-Y., Heng, D. Y. C., North, S. A., Emmenegger, U., Hotte, S. J., Chi, K., Zielinski, R., Al-Shamsi, H. O., Chen, L., et al. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.1891 · Cited by 8
Martins, A. G. G. D. M., Allegretta, G., Unteregger, G., Haupenthal, J., Eberhard, J., Hoffmann, M., van der Zee, J. A., Junker, K., Stöckle, M., Müller, R., et al. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.09.006 · Cited by 8
Celebrating the 80th anniversary of hormone ablation for prostate cancer
Zoubeidi, A., & Ghosh, P. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0192 · Cited by 11
Steroids: reactions and partial synthesis
Hanson, J. R. (1997) · Natural Product Reports · doi:10.1039/np9971400373 · Cited by 8
Sex Hormones (Male): Analogs and Antagonists
Brueggemeier, R. W. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200500066 · Cited by 9
Sorrentino, C., D’Angiolo, R., Gentile, G., Giovannelli, P., Perillo, B., Migliaccio, A., Castoria, G., & Donato, M. D. (2023) · Endocrines · doi:10.3390/endocrines4020027 · Cited by 8
Kaku, T., Tsujimoto, S., Matsunaga, N., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., & Tasaka, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.009 · Cited by 7
Ternov, K. K., Sønksen, J., Fode, M. M., Lindberg, H., Kistorp, C., Bisbjerg, R., Palapattu, G. S., & Østergren, P. B. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030218 · Cited by 8
Cirillo, P. F., Caccavale, A., & DeLuna, A. (2020) · Journal of Chemical Education · doi:10.1021/acs.jchemed.0c00991 · Cited by 7
Haidar, S., Klein, C. D. P., & Hartmann, R. W. (2001) · Archiv der Pharmazie · doi:10.1002/1521-4184(200104)334:4 · Cited by 7
Neighboring group participation
Szájli, Á., Woelfling, J., Mernyák, E., Minorics, R., Márki, Á., Falkay, G., & Schneider, G. (2005) · Steroids · doi:10.1016/j.steroids.2005.09.008 · Cited by 7
Tan, J. S., Sathianathen, N. J., Geurts, N., Nair, R., Murphy, D. G., & Lamb, A. D. G. (2017) · Urological Science · doi:10.1016/j.urols.2017.10.001 · Cited by 9
Kiss, A., Herman, B. E., Görbe, T., Mernyák, E., Molnár, B., Woelfling, J., Szécsi, M., & Schneider, G. (2018) · Steroids · doi:10.1016/j.steroids.2018.03.006 · Cited by 7
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic
Salvador, J. A. R., Vania, M., & Silvestre, S. (2013) · InTech eBooks · doi:10.5772/52290 · Cited by 10
Bahshwan, S. A., Owen, C. P., Nicholls, P. J., Smith, H. J., & Ahmadi, M. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb03320.x · Cited by 7
Male Sex Hormones, Analogs, and Antagonists
Brueggemeier, R. W. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc055 · Cited by 7
Eremeev, R. O., Dubinina, T. V., Burtsev, I. D., Markova, A. A., Borisova, N. E., Ivanova, M. M., Belousov, M. S., Kosov, A. D., Khabibullin, V. R., Proskurnin, М. А., et al. (2025) · Dyes and Pigments · doi:10.1016/j.dyepig.2025.112868 · Cited by 6
Stulov, S., Dugin, N. O., Zharkova, M. S., Shcherbinin, D. S., Kuzikov, A. V., Shumantseva, V. V., Misharin, A. Y., & Veselovsky, A. V. (2015) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750815020134 · Cited by 6
Functionalization of Pyridines at the C4 Position via Metalation and Capture
Hsu, H., Kang, S., Chen, C., Sk, M. R., & Thomas, A. A. (2025) · Angewandte Chemie · doi:10.1002/ange.202424172 · Cited by 6
Stulov, S., Dugin, N. O., Zharkova, M. S., Shcherbinin, D. S., Kuzikov, A. V., Shumyantseva, V. V., Misharin, A. Y., & Veselovsky, A. V. (2016) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20166201038 · Cited by 6
Sheng, I. Y. F., Fallah, J., Gupta, R., Li, H., Allman, K. D., Martin, A. M., Barata, P. C., Ornstein, M. C., Gilligan, T. D., Rini, B. I., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00734-w · Cited by 6
Shirazi, S. M. H., Mokhtari, J., & Mirjafary, Z. (2021) · Applied Organometallic Chemistry · doi:10.1002/aoc.6477 · Cited by 6
Wang, Y., Zhang, S. C., Li, H., Zhi, H., & Wu, H. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i23.5547 · Cited by 6
Cicero, G., Luca, R. D., Blasi, L., Pepe, A., Pavone, C., Simonato, A., & Dieli, F. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000549 · Cited by 6
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · ChemInform · doi:10.1002/chin.199544212 · Cited by 6
Self-citationSolum, E. J., Liekens, S., & Hansen, T. V. (2020) · Molecules · doi:10.3390/molecules25133052 · Cited by 6
Procopio, G., Chiurì, V. E., Giordano, M., Alitto, A. R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., Placido, S. D., Airoldi, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100431 · Cited by 7
Chemotherapeutic inhibitors in the treatment of prostate cancer
Deshmukh, R. R., Schmitt, S. M., Hwang, C., & Dou, Q. P. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.852184 · Cited by 7
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Chetia, A., Saikia, A. K., Saikia, C. J., & Boruah, R. C. (2003) · Tetrahedron Letters · doi:10.1016/s0040-4039(03)00324-1 · Cited by 6
SYNTHESIS OF MODIFIED STEROIDS IN THE ANDROSTANE AND ANDROSTENE SERIES
Stéphan, É. (2006) · Organic Preparations and Procedures International · doi:10.1080/00304940609355990 · Cited by 6
Houédé, N., Beuzeboc, P., Gourgou, S., Tosi, D., Moise, L., Gravis, G., Delva, R., Fléchon, A., Latorzeff, I., Ferrero, J.-M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.7_suppl.264 · Cited by 7
Beller, M., Varela‐Fernández, A., de Vries, J. G., Wong, S. M., So, C. M., & Kwong, F. Y. (2017) · doi:10.1002/9783527651733.ch6 · Cited by 6
Bianchini, D., & Bono, J. S. D. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70164-2 · Cited by 5
Oklješa, A. M., Raičević, V., Jakimov, D., & Klisurić, O. R. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132577 · Cited by 5
Zolottsev, V. А., Latysheva, А. S., Khan, I. I., Pokrovsky, V. S., & Misharin, A. Y. (2022) · ChemistrySelect · doi:10.1002/slct.202203393 · Cited by 5
Noncanonical Mechanisms to Regulate Nuclear Receptor Signaling
Sadana, P. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.72 · Cited by 6
Green Suzuki Coupling Reaction for Synthesis of Abiraterone Acetate and its Analogues
Bian, X., Wang, L., Liu, J., & Wang, C. (2016) · Journal of Chemical Research · doi:10.3184/174751916x14604710386405 · Cited by 5
Crystal structure of (3S)-3-acetoxy-17-(pyridin-3-yl)androsta-5,16-diene
Zhou, S., Huang, H.-Q., & Huang, R. (2015) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989015001966 · Cited by 5
Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity
Sucman, N. S., Bilan, D. Y., Cojocari, S., Pogrebnoi, V., Stingaci, E., Khripach, V. A., Zhabinskii, V. N., Tsybruk, T. V., Grabovec, I. P., Panibrat, O. V., et al. (2024) · Steroids · doi:10.1016/j.steroids.2024.109475 · Cited by 4
Bekkar, Y., Lanez, E., Al-Masoudi, N. A., Abdul-Rida, N. A., Al‐Masoudi, W. A., & Mahdi, A. M. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00626-3 · Cited by 4
Lokeshwar, S. D., Choksi, A. U., Haltstuch, D., Rahman, S. N., Press, B. H., Syed, J. S., Hurwitz, M. E., Kim, I. Y., & Leapman, M. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04409-9 · Cited by 4
Hu, C., Zhang, H., Zhang, M., Mi, Z., Wang, J., Lu, W., & Su, J. (2018) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmy065 · Cited by 4
Abiraterone in prostate cancer.
Ryan, C. J. (2010) · PubMed · Cited by 4
Metadata
- Authors
- Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-06
- Volume
- 38
- Issue
- 13
- Pages
- 2463-2471
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2027081726
- Cited by
- 379
- References
- 33
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 21 · 2016: 20 · 2015: 21 · 2014: 28 · 2013: 31 · 2012: 28
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- CYP17 inhibitors, steroids, palladium-catalyzed cross-coupling, structure-activity relationship, steroid synthesis, prostate cancer, hormone-dependent prostate cancer, androstenedione, pregnenolone, progesterone
- MeSH terms
- Humans, Male, Magnetic Resonance Spectroscopy, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroids, Structure-Activity Relationship, Testis, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.